Lung Cancer

Australian oncologists identify a new biomarker to guide immunotherapy in NSCLC

HLA-I homozygosity is linked to poor outcomes with immunotherapy in patients with lung cancer and may have value in guiding treatment decisions, according to WA researchers. A study involving 170 patients with advanced NSCLC showed that homozygosity at one or more HLA-I loci was associated with poor survival outcomes with anti-PD1 or anti-PDL1 therapy. The ...

Already a member?

Login to keep reading.

© 2021 the limbic